

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

MIRABEGRON EXTENDED-RELEASE TABLETS OBTAINS DRUG REGISTRATION APPROVAL

The board of directors (the “**Board**”) of the CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Mirabegron Extended-Release Tablets (the “**Product**”) developed by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd* (石藥集團中諾藥業(石家莊)有限公司), a subsidiary of the Company, has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China, and is deemed to have passed the consistency evaluation of quality and efficacy of generic drugs.

Mirabegron is a selective β_3 adrenergic receptor agonist that relaxes bladder smooth muscles by acting on bladder tissues. It is used for symptomatic treatment of urgent urination, frequent urination and/or urge incontinence in adults with overactive bladder (OAB).

The approval of the Product will further enrich the Group’s product portfolio and provide an additional choice for the treatment of patients with overactive bladder in China.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 14 June 2023

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.

** For identification purposes only*